Axsome Therapeutics, Inc.
AXSM
Rangering i aksjer
#2362
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aksjekurs
$159.65
Sist synkronisert: 2026-10-20
Markedsverdi
$8.36B
Endring (1 dag)
2.46%
Endring (1 år)
21.51%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategori
Healthcare
P/S-forhold for Axsome Therapeutics, Inc. (AXSM)
P/S-forhold per October 2026 TTM: 10.75
Ifølge Axsome Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 10.75. Ved slutten av 2023 hadde selskapet et P/S-forhold på 13.36.
P/S-historikk for Axsome Therapeutics, Inc. fra 2013 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 10.75 | 2.28% |
| 2024 | 10.51 | -21.33% |
| 2023 | 13.36 | -78.68% |
| 2022 | 62.67 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -6.77% |
US
|
|
| 40.55 | 277.23% |
US
|
|
| 3.96 | -63.15% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -5.61% |
NL
|
